Quanzhou, China, 1 December 2017 – Fresenius Medical Care (FME), the global market leader in dialysis, launched last week in Quanzhou its first independent dialysis center in China.
“The opening of our first independent and stand-alone Fresenius Medical Care dialysis center in Quanzhou is another important milestone for us on the way to further expand our business in China”, said Harry de Wit, CEO of Fresenius Medical Care Asia Pacific. “By working closely with the Fujian government, we built the center in order to perfectly meet the needs of kidney patients in the region”.
Located in the Licheng District of Quanzhou, the centre offers treatment at 50 dialysis stations. Multiple dialysis modalities from high-flux haemodialysis to haemodiafiltration are provided. The center launched as Fresenius Kidney Care Quanzhou Dialysis Center aims to provide high quality and safe dialysis as well as other related medical services for patients with Chronic Kidney Disease.
The Fujian Province is at the forefront of China’s new medical reform movement that promotes the collaboration between public and private medical providers. At the beginning of 2017 the Fujian Provincial Health and Family Planning Commission published the „Notice on the Planning, Creation, Registration and Management of Dialysis Centers”. It especially encourages private dialysis providers to further promote close support between public hospitals and non-public medical institutions. The newly-established dialysis center of Fresenius Medical Care in Quanzhou serves as a successful example for Fujian to adopt leading medical practices and well trained medical staff in their health care provision to deliver high-quality services.
China is one of the largest dialysis markets worldwide and will become increasingly more important in the future. Fresenius Medical Care has already been providing dialysis products in China since 1993 and strongly expanded its product business in the recent years. Additionally, Fresenius Medical Care is evaluating opportunities to collaborate with public and private sector partners to expand its dialysis services business in China.
ABOUT FRESENIUS MEDICAL CARE
Fresenius Medical Care is the world's largest provider of products and services for individuals with renal diseases of which around 3 million patients worldwide regularly undergo dialysis treatment. Through its network of 3,714 dialysis clinics, Fresenius Medical Care provides dialysis treatments for 317,792 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Along with the core business, the company focuses on expanding the range of related medical services in the field of Care Coordination. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS).
This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including changes in business, economic and competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.